Available Genomic Tests for Clinically Localized Prostate Cancer

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

EP: 1.Staging, Grading, and Risk Stratification of Prostate Cancer

EP: 2.Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP: 3.Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP: 4.The Potential for Overtreatment or Undertreatment of Prostate Cancer

EP: 5.Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

Now Viewing

EP: 6.Available Genomic Tests for Clinically Localized Prostate Cancer

EP: 7.Clinical Study Data in Prostate Cancer Genomic Testing

EP: 8.Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

EP: 9.Exciting Emerging Data in Prostate Cancer

Related Videos

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.